This is consistent with the known lower prevalence of HER2 expression or ERBB2 amplification in invasive lobular carcinomas (14, 15) and the fact that lobular carcinomas more frequently present a HER2–0 phenotype (15). This evidence concerns the gene ERBB2 and breast lobular carcinoma.